Not exact matches
Listed Perth company AnaeCo has announced plans for a $ 21.4 million rights issue pitched
at lesss
than half its
current share price, as it seeks to complete its first waste
treatment plant in Shenton
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in
treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and
current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Current chemotherapy
treatments cure the disease in fewer
than 10 % of patients who have a FLT3 mutation — partly because toxic chemotherapy drugs can be used for only a few days
at a time, not killing as many cancer cells as they might.
«
Current guidelines recommend that
treatment of subclinical hyperthyroidism should be strongly considered if TSH is persistently lower
than 0.1 mIU / L in all individuals aged 65 years or older and that
treatment should also be considered if TSH is low but
at least 0.1 mIU / L in individuals who are
at least 65 years old.
Testing their microparticles in mice, the team found that the drug persisted in their eyes for
at least 14 weeks, more
than three times as long as the
current treatment.
«Despite having good
treatments available,
current reports suggest that fewer
than half of individuals who need therapy are actually getting appropriate HIV medicine to control their virus, leading to more transmission of disease,» says lead study author Maunank Shah, M.D., Ph.D., an assistant professor of medicine
at the Johns Hopkins University School of Medicine.
They found that by elevating the activity of PV - GPe neurons over the activity of the Lhx6 - GPe neurons, they were able to stop aberrant neuronal behavior in the basal ganglia and restore movement in the mouse model for
at least four hours — significantly longer
than current treatments.
In patients whose colon cancer has spread (most often to the liver),
current treatments extend life by,
at most, less
than two years.
Issuing Company: ETF Securities Ltd Ticker: PPLT Expense Ratio: 0.60 % Tax
Treatment: From the prospectus, «Under
current law, gains recognized by individuals from the sale of «collectibles,» including physical platinum, held for more
than one year are taxed
at a maximum federal income tax rate of 28 %, rather
than the 15 % rate applicable to most other long - term capital gains.»
Beck felt that this contradicted contemporary thinking about depression, as he felt that
treatments for depression
at the time focused too much on previous experiences rather
than on
current day - to - day beliefs and experiences.
Although more
than a third of their children had a
current psychiatric disorder
at baseline and more
than half had a lifetime history, some improvement was observed in the children in a relatively short time, ie, 3 months, and this occurred, in most cases, without the children receiving direct
treatment.
Eligible couples 1) had to be
at least 25 years old; 2) had to be exclusively involved and living together for
at least one year; 3) could not have been previously diagnosed with a psychotic disorder, or currently taking any medication known to treat psychosis or psychotic disorders; 4) could not be receiving
current psychotherapeutic (psychological or psychiatric)
treatment or anticipating such
treatment within the next six months; 5) could not be drinking more
than 14 alcoholic drinks per week, using any type of illegal drugs, or misusing prescription medication; and 6) could not have a history of either childhood or adulthood physical or sexual abuse.